Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Apr;31(4):463–469. doi: 10.1111/j.1365-2125.1991.tb05563.x

Analysis of the natriuretic action of a loop diuretic, piretanide, in man.

F H Noormohamed 1, A F Lant 1
PMCID: PMC1368335  PMID: 2049256

Abstract

1. The renal responses to a loop diuretic, piretanide, were investigated in a group of fourteen healthy volunteers. The effect of fluid replacement on the drug-response relationship was evaluated in the absence and in the presence of probenecid pretreatment following both oral and intravenous administration of piretanide. 2. Urinary excretion of piretanide was greater when volume losses were replaced than in the absence of volume replacement (i.v. dose: 3.32 +/- 0.15 vs 2.55 +/- 0.23 mg 6 h-1, P less than 0.01; oral dose: 2.57 +/- 0.09 vs 1.87 +/- 0.27 mg 6 h-1, P less than 0.01). With intravenous piretanide urinary excretion of sodium was likewise greater in the fluid replaced group (198 +/- 4 vs 141 +/- 10 mmol 6 h-1, P less than 0.01); these differences caused by fluid replacement did not however occur after oral dosing of piretanide (181 +/- 12 vs 167 +/- 14 mmol 6 h-1). 3. Probenecid pretreatment significantly decreased the renal excretion of piretanide in all subjects and consistently decreased the natriuretic response with the exception of intravenous piretanide challenge in subjects not undergoing fluid replacement. In this situation, despite probenecid causing a decrease in the amount of drug excreted (2.55 +/- 0.23 vs 1.63 +/- 0.15 mg 6 h-1, P less than 0.05) the sodium output was unaltered (141 +/- 10 vs 152 +/- 16 mmol 6 h-1, NS). 4. Complete replacement of the induced fluid losses resulted in the enhancement of the renal response, without affecting the shape of the diuretic response curve, of either the intravenous or orally administered piretanide.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
465

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ala-Houhala I., Vapaatalo H., Pasternack A. Intravenously administered frusemide increases glomerular permeability. Clin Sci (Lond) 1987 Oct;73(4):365–370. doi: 10.1042/cs0730365. [DOI] [PubMed] [Google Scholar]
  2. Andreasen F., Lauridsen I. N., Hansen F. A., Christensen S., Steiness E. Dose dependency of furosemide-induced sodium excretion. J Pharmacol Exp Ther. 1989 Mar;248(3):1182–1188. [PubMed] [Google Scholar]
  3. Branch R. A. Role of binding in distribution of furosemide: where is nonrenal clearance? Fed Proc. 1983 Apr;42(6):1699–1702. [PubMed] [Google Scholar]
  4. Brater D. C. Determinants of the overall response to furosemide: pharmacokinetics and pharmacodynamics. Fed Proc. 1983 Apr;42(6):1711–1713. [PubMed] [Google Scholar]
  5. Chennavasin P., Seiwell R., Brater D. C., Liang W. M. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int. 1979 Aug;16(2):187–195. doi: 10.1038/ki.1979.120. [DOI] [PubMed] [Google Scholar]
  6. Cook J. A., Smith D. E. Development of acute tolerance to bumetanide: bolus injection studies. Pharm Res. 1987 Oct;4(5):379–384. doi: 10.1023/a:1016426110571. [DOI] [PubMed] [Google Scholar]
  7. Dixey J. J., Noormohamed F. H., Pawa J. S., Lant A. F., Brewerton D. A. The influence of nonsteroidal anti-inflammatory drugs and probenecid on the renal response to and kinetics of piretanide in man. Clin Pharmacol Ther. 1988 Nov;44(5):531–539. doi: 10.1038/clpt.1988.190. [DOI] [PubMed] [Google Scholar]
  8. Hammarlund-Udenaes M., Benet L. Z. Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update. J Pharmacokinet Biopharm. 1989 Feb;17(1):1–46. doi: 10.1007/BF01059086. [DOI] [PubMed] [Google Scholar]
  9. Hammarlund M. M., Odlind B., Paalzow L. K. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1985 May;233(2):447–453. [PubMed] [Google Scholar]
  10. Homeida M., Roberts C., Branch R. A. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man. Clin Pharmacol Ther. 1977 Oct;22(4):402–409. doi: 10.1002/cpt1977224402. [DOI] [PubMed] [Google Scholar]
  11. Honari J., Blair A. D., Cutler R. E. Effects of probenecid on furosemide kinetics and natriuresis in man. Clin Pharmacol Ther. 1977 Oct;22(4):395–401. doi: 10.1002/cpt1977224395. [DOI] [PubMed] [Google Scholar]
  12. Kaojarern S., Day B., Brater D. C. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int. 1982 Jul;22(1):69–74. doi: 10.1038/ki.1982.134. [DOI] [PubMed] [Google Scholar]
  13. Lee M. G., Li T., Chiou W. L. Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. Biopharm Drug Dispos. 1986 Nov-Dec;7(6):537–547. doi: 10.1002/bdd.2510070603. [DOI] [PubMed] [Google Scholar]
  14. Li T., Lee M. G., Chiou W. L. Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide. J Pharmacokinet Biopharm. 1986 Oct;14(5):495–509. doi: 10.1007/BF01059657. [DOI] [PubMed] [Google Scholar]
  15. Lu W., Endoh M., Katayama K., Kakemi M., Koizumi T. Pharmacokinetic and pharmacodynamic studies of piretanide in rabbits. I. Effect of different hydrated conditions. J Pharmacobiodyn. 1987 Aug;10(8):356–363. doi: 10.1248/bpb1978.10.356. [DOI] [PubMed] [Google Scholar]
  16. McNabb W. R., Noormohamed F. H., Lant A. F. Acute and long-term renal and metabolic effects of piretanide in congestive cardiac failure. Br J Clin Pharmacol. 1988 Aug;26(2):143–154. doi: 10.1111/j.1365-2125.1988.tb03380.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Noormohamed F. H., McNabb W. R., Dixey J. J., Lant A. F. Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment. J Pharmacol Exp Ther. 1990 Sep;254(3):992–999. [PubMed] [Google Scholar]
  18. Noormohamed F. H., McNabb W. R., Lant A. F. Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. J Pharmacol Exp Ther. 1990 Apr;253(1):362–368. [PubMed] [Google Scholar]
  19. Odlind B., Beermann B., Lindström B. Coupling between renal tubular secretion and effect of bumetanide. Clin Pharmacol Ther. 1983 Dec;34(6):805–809. doi: 10.1038/clpt.1983.253. [DOI] [PubMed] [Google Scholar]
  20. Odlind B., Beermann B. Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther. 1980 Jun;27(6):784–790. doi: 10.1038/clpt.1980.111. [DOI] [PubMed] [Google Scholar]
  21. Pillay V. K., Gandhi V. C., Sharma B. K., Smith E. C., Dunea G. Effect of hydration and furosemide given intravenously on proteinuria. Arch Intern Med. 1972 Jul;130(1):90–92. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES